Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

Pfizer Inc. (NYSE: PFE) announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer’s pending acquisition of Seagen Inc. (NASDAQ: SGEN). Pfizer and Seagen have now received all required regulatory approvals to complete the acquisition. Pfizer expects to close the acquisition of Seagen on December 14, 2023, subject to the satisfaction of other customary closing conditions. To address U.S. Federal Trade Commission concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of Bavencio® (avelumab) in the U.S. to the American Association for Cancer Research (AACR).

Read the full article: Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen //

Source: https://www.businesswire.com/news/home/20231212889916/en/Pfizer-Receives-All-Required-Regulatory-Approvals-to-Complete-the-Acquisition-of-Seagen

Leave a Comment

Your email address will not be published.

Scroll to Top